ALAMEDA, Calif. — January 27, 2026 — Leads & Copy — Vivani Medical, Inc. (Nasdaq: VANI) closed its previously announced best efforts registered direct offering of 1,689,200 shares of its common stock at $1.48 per share and a concurrent private placement of 1,351,351 shares of its common stock at $1.48 per share.
Gregg Williams, the Chairman of the Company’s board of directors, purchased the shares in the private placement. The gross proceeds from the two transactions totaled approximately $4.5 million, before deducting fees and offering expenses.
The registered offering and the private placement were priced “at-the-market” under the rules and regulations of The Nasdaq Stock Market LLC.
Vivani intends to use the net proceeds from the registered offering and private placement to fund ongoing research and clinical development of its product candidates, as well as for working capital and general corporate purposes.
ThinkEquity acted as sole placement agent for the registered direct offering.
The securities in the registered direct offering were offered and issued pursuant to a shelf registration statement on Form S-3 (File No. 333-278869), including a base prospectus, filed with the U.S. Securities and Exchange Commission (the “SEC”) on April 22, 2024 and declared effective on May 3, 2024. The offering was made only by means of a written prospectus. A final prospectus supplement and accompanying prospectus describing the terms of the offering was filed with the SEC and is available on its website at www.sec.gov. Copies of the final prospectus supplement and the accompanying prospectus relating to the offering may also be obtained, when available, from the offices of ThinkEquity, 17 State Street, 41st Floor, New York, New York 10004.
This press release does not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or other jurisdiction.
Vivani Medical, Inc. develops biopharmaceutical implants designed to deliver drug molecules steadily over extended periods of time. Vivani is developing a portfolio of GLP-1 based implants for metabolic diseases including obesity and type 2 diabetes. Its proprietary NanoPortal™ platform aims to guarantee adherence and improve patient tolerance to their medication.
These NanoPortal implants are designed to provide patients with the opportunity to realize the full potential benefit of their medication by avoiding the numerous challenges associated with the daily or weekly administration of orals and injectables, including tolerability issues and loss of efficacy.
Medication non-adherence affects approximately 50% of patients, including those taking daily pills.
Source: Vivani Medical, Inc.
